| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Corticotropin-releasing hormone receptor 1 (CRHR1). JTC-017 acts as a competitive antagonist at CRHR1, blocking the binding of corticotropin-releasing hormone (CRH) and preventing downstream signaling. This inhibits CRH-mediated activation of the hypothalamic-pituitary-adrenal (HPA) axis and reduces stress-induced behaviors and physiological responses.
|
|---|---|
| ln Vitro |
JTC-017 is a specific CRHR1 antagonist with high affinity and selectivity. It attenuates hippocampal noradrenaline release, visceral perception, and ACTH release in rats. The compound is brain-penetrant and effectively blocks stress-induced changes in colonic motility after chronic colorectal distention.
|
| ln Vivo |
In vivo, JTC-017 attenuates stress-induced visceral perception, anxiety, and ACTH release in rat models of acute colorectal distention. It also blocks stress-induced changes in colonic motility after chronic colorectal distention, suggesting therapeutic potential for IBS.
|
| Enzyme Assay |
CRHR1 binding assays use membranes from cells expressing recombinant CRHR1. Radiolabeled CRH or a selective CRHR1 antagonist (e.g., [125I]CRH or [3H]CP-154,526) is incubated with the membranes in the presence of increasing concentrations of JTC-017. Bound radioactivity is separated by filtration and measured by scintillation counting to determine binding affinity and selectivity.
|
| Cell Assay |
Cell-based functional assays use cells expressing CRHR1 and a cAMP-responsive reporter gene. JTC-017 is pre-incubated with the cells, followed by stimulation with CRH. The inhibition of CRH-induced cAMP accumulation is measured to determine antagonist potency.
|
| Animal Protocol |
In vivo studies use rat models of acute and chronic colorectal distention. JTC-017 is administered systemically, and visceral perception (measured by abdominal withdrawal reflex), hippocampal noradrenaline release (measured by microdialysis), and ACTH levels (measured by radioimmunoassay) are assessed. Colonic motility is measured after chronic colorectal distention.
|
| References |
| Molecular Formula |
C20H25CL2N3O5S
|
|---|---|
| Molecular Weight |
490.39
|
| Exact Mass |
489.089
|
| CAS # |
357330-77-9
|
| PubChem CID |
10163420
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.521
|
| tPSA |
111.05
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
689
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(=C(C=C(C=1)C(NC1C(=C(C=C(C=1)S(N(CC)CC)(=O)=O)N(C)C)OC)=O)Cl)O
|
| InChi Key |
DFHUSLVYQHBBEV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H25Cl2N3O5S/c1-6-25(7-2)31(28,29)13-10-16(19(30-5)17(11-13)24(3)4)23-20(27)12-8-14(21)18(26)15(22)9-12/h8-11,26H,6-7H2,1-5H3,(H,23,27)
|
| Chemical Name |
3,5-dichloro-N-[5-(diethylsulfamoyl)-3-(dimethylamino)-2-methoxyphenyl]-4-hydroxybenzamide
|
| Synonyms |
JTC017; JTC 017; JTC-017
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0392 mL | 10.1960 mL | 20.3919 mL | |
| 5 mM | 0.4078 mL | 2.0392 mL | 4.0784 mL | |
| 10 mM | 0.2039 mL | 1.0196 mL | 2.0392 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
